• What is the Active Ingredient in FMT for CDI?

What is the Active Ingredient in FMT for CDI?

Sterile fecal filtrates—containing bacterial debris, proteins, antimicrobial compounds, metabolic products, and microbial DNA, rather than intact microorganisms—appear to be effective for treatment of recurrent Clostridium difficile infection (CDI), researchers report in the March issue of Gastroenterology. Fecal microbiota transplantation (FMT) is an effective therapy of recurrent CDI—a single treatment resolves

Read more
  • An Effective and Long-lasting Hepatitis E Vaccine

An Effective and Long-lasting Hepatitis E Vaccine

A long-term study of a hepatitis E virus (HEV) vaccine showed that it is 86.8% effective and that immunity can last for up to 4.5 years. In a blinded, placebo-controlled, phase 3 trial, Jun Zhang et al randomly assigned 112,604 healthy adults in Dongtai (in the Jiangsu province of China)

Read more
  • What is the Best Treatment Strategy for Hepatitis B?

What is the Best Treatment Strategy for Hepatitis B?

Response-guided interferon therapy is the most cost-effective first-line treatment for hepatitis B e antigen (HBeAg)-positive patients, whereas nucleos(t)ide analogues are the most cost-effective first-line therapy for HBeAg-negative patients, researchers report in the February issue of Clinical Gastroenterology and Hepatology. Pegylated interferon and nucleos(t)ide analogues are recommended first-line treatment options for

Read more
  • A New Approach to Hepatitis B Therapy?

A New Approach to Hepatitis B Therapy?

Cyclophilins are involved in multiple steps of the hepatitis B virus (HBV) life cycle in hepatocytes—cyclophilin inhibitors reduce viral replication and HBV envelope protein production and secretion, researchers report in the February issue of Gastroenterology. The cyclophilin inhibitor alisporivir, combined with the HBV polymerase inhibitor, reduces markers of HBV infection

Read more

Are Patients Receiving the Latest Anti-HCV Drugs?

Less than 20% of patients infected with the most common Hepatitis C virus (HCV) genotype receive the latest drugs approved by the US Food and Drug Administration (FDA), according to the August issue of Clinical Gastroenterology and Hepatology. This low percentage could result from concerns of side effects or patient

Read more

Is SVR12 As Good As SVR24?

In patients with chronic Hepatitis C virus (HCV) infection, a sustained viral response to treatment regimens 12 weeks after therapy (SVR12) is a good indicator that the response will be maintained until week 24 (SVR 24), based on an analysis of pooled clinical trial data published in the June issue of

Read more

What Factors Predict Recovery From Chronic HBV Infection?

A low and rapidly decreasing level of Hepatitis B surface antigen (HBsAg) is a good sign for patients with chronic HBV infection, according to the March issue of Clinical Gastroenterology and Hepatology. Tracking progression of chronic HBV infection can be complicated—patients can have high viral loads with no symptoms, and

Read more